Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11665099 | 0.78 | MEN1 (0.60) | BRD4MEN1KMT2AATMGAA | |
| SCHEMBL16109306 | 0.76 | GAA (0.60) | BRD4MEN1KMT2AGAACYP1A2 | |
| SCHEMBL9539830 | 0.74 | BRD4 (0.52) | BRD4MEN1KMT2AGAA | |
| SCHEMBL19411635 | 0.71 | PGR (0.45) | LPLLIPGPRMT5WDR77 | |
| SCHEMBL12873509 | 0.71 | LIPG (0.51) | LPLLIPGP4HB | |
| SCHEMBL16282601 | 0.70 | LIPG (0.50) | LPLLIPGPRMT5WDR77P4HB | |
| SCHEMBL19411831 | 0.70 | PIK3CD (0.43) | BRD4LPLLIPGPRMT5WDR77 | |
| SCHEMBL16108870 | 0.68 | BRD4 (1.00) | BRD4 | |
| SCHEMBL16108904 | 0.68 | BRD4 (1.00) | BRD4 | |
| SCHEMBL18488019 | 0.68 | LIPG (0.47) | LPLLIPGP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978758-B1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-2978758-B1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-2978758-A1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-02-03 | — | — | EP | disclosed |
| US-9199988-B2 | Dihydroquinazolinone analogues | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199988-B2 | Dihydroquinazolinone analogues | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20140296230-A1 | DIHYDROQUINAZOLINONE ANALOGUES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140296230-A1 | DIHYDROQUINAZOLINONE ANALOGUES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| WO-2014154762-A1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154762-A1 | DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296230-A1 | DIHYDROQUINAZOLINONE ANALOGUES | MKI67, NQO2, CCNI | BRD4 1359/4885LPL 4739/4885LIPG 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.